A Study of Abemaciclib in Recurrent Glioblastoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Eudocia Q Lee, MD MPH
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California Los Angeles
Los Angeles, California, United States
- University of California, San Francisco
San Francisco, California, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Ut, M.D. Anderson Cancer Center
Houston, Texas, United States
- Huntsman Cancer Institute
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Feb 2017
- Primary completion
- 30 Jun 2024
- Completion
- 30 Jun 2026
- Last update posted
- 2 Sept 2025
- Registered enrollment
- 45
- Registry id
- NCT02981940
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.